The following sample deal entries offer an insight into the level of detail you can expect when subscribing to Current Agreements.

Partnering deals

Licensing, development and option agreement for QPI-1002

Quark has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial more

Asset purchase agreement for follow-on biologics platform

Merck, through an affiliate, will purchase all assets related to Insmed's follow-on biologics platform more

M&A deals

Acquisition agreement for Penwest Pharmaceuticals

Endo will commence an all-cash tender offer to acquire 100 percent of the outstanding common stock of Penwest Pharmaceuticals for $5.00 per Penwest share or $144 million more

Deals Update newsletter

Signup to receive our free monthly Deals Update newsletter.